The University of Nebraska Medical Center and Nebraska Medicine is involved in a clinical research study to test the safety and effectiveness of the Novavax COVID-19 vaccine for adolescents (aged 12-17).
STATUS: NO LONGER ENROLLING PARTICIPANTS
Enrollment has closed and we will not be able to accept any new participants.
For this study, the medical center is working with the COVID-19 Prevention Network (COVPN), formed by the National Institute of Allergy and Infectious Diseases (NIAID) at the US National Institutes of Health to respond to the global pandemic.
Diana Florescu, MD, a professor and infectious diseases specialist in the UNMC Department of Internal Medicine, is leading the Phase 3 clinical study at UNMC.
“We are excited to continue this study at UNMC, now looking at a younger population. We hope that this SARS CoV-2 vaccine will also be shown to prevent the disease in adolescents.”
Diana Florescu, MD
This study is what is called a 2:1 randomized study, meaning when the two initial injections are given, some people (2 out of 3) will be given the actual study vaccine and some (1 out of 3) will get a version that does not have any medication (placebo). After six months, an additional two injections will be given, at which time those who received the placebo will receive the study vaccine, and those who received the study vaccine will receive the placeo. Therefore, all participants will receive the study vaccine. Follow-up monitoring will be performed over the course of two years.
The study is looking for adolescents who are:
- 12 to 17 years of age;
- have NOT previously tested positive for COVID-19/SARS-CoV-2/Coronavirus;
- are medically stable, with no changes to medications in the past two months; and
- are NOT pregnant, breastfeeding, or planning to become pregnant.
If you are interested in enrolling, click the ‘Register Now’ button at the top of the page. IRB# 727-20-CB